PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9379848-3	1997	Regionally, 32 days treatment with haloperidol (3 mg/kg/day), sulpiride (100 mg/kg/day) or clozapine (10 mg/kg/day) resulted in a drop of approximately 30-40% in 5HT2C mRNA levels in both cortex and cerebellum, and decreases (or non-significant trends) of 15-40% in 5HT2A mRNA levels in hippocampus, brainstem and mid brain.	Haloperidol	35-46	5-hydroxytryptamine receptor 2C	Rattus norvegicus	162-167	
15986194-0	2005	Enhanced 5-HT2C receptor signaling is associated with haloperidol-induced "early onset" vacuous chewing in rats: implications for antipsychotic drug therapy.	Haloperidol	54-65	5-hydroxytryptamine receptor 2C	Rattus norvegicus	9-15	
15986194-5	2005	OBJECTIVES: In the present study, we tested the hypothesis that repeated daily administration of haloperidol leads to enhanced serotonin 5-HT2C receptor signaling that is associated with increased 5-HT2C-mediated VCM.	Haloperidol	97-108	5-hydroxytryptamine receptor 2C	Rattus norvegicus	137-143	
15986194-5	2005	OBJECTIVES: In the present study, we tested the hypothesis that repeated daily administration of haloperidol leads to enhanced serotonin 5-HT2C receptor signaling that is associated with increased 5-HT2C-mediated VCM.	Haloperidol	97-108	5-hydroxytryptamine receptor 2C	Rattus norvegicus	197-203	
15986194-13	2005	Striatal 5-HT2C receptor-mediated phospholipase C (PLC) activity and high-affinity agonist-labeled 5-HT2C receptors were also increased following either dose of haloperidol as compared to vehicle treatment.	Haloperidol	161-172	5-hydroxytryptamine receptor 2C	Rattus norvegicus	9-15	
15986194-13	2005	Striatal 5-HT2C receptor-mediated phospholipase C (PLC) activity and high-affinity agonist-labeled 5-HT2C receptors were also increased following either dose of haloperidol as compared to vehicle treatment.	Haloperidol	161-172	5-hydroxytryptamine receptor 2C	Rattus norvegicus	99-105	
15986194-15	2005	CONCLUSIONS: Repeated daily administration of haloperidol leads to an adaptive increase in 5-HT2C signaling which may contribute to abnormal motor function associated with antipsychotic use.	Haloperidol	46-57	5-hydroxytryptamine receptor 2C	Rattus norvegicus	91-97	
15917433-6	2005	Whereas haloperidol, a typical antipsychotic drug that is primarily a dopamine receptor antagonist, reduced 5-HT2C VNV isoform frequency and the level of RNA editing at the D site, risperidone and not the prototype atypical antipsychotic drug clozapine increased the frequency of 5-HT2C VNV and D-site editing.	Haloperidol	8-19	5-hydroxytryptamine receptor 2C	Rattus norvegicus	108-114	
15917433-6	2005	Whereas haloperidol, a typical antipsychotic drug that is primarily a dopamine receptor antagonist, reduced 5-HT2C VNV isoform frequency and the level of RNA editing at the D site, risperidone and not the prototype atypical antipsychotic drug clozapine increased the frequency of 5-HT2C VNV and D-site editing.	Haloperidol	8-19	5-hydroxytryptamine receptor 2C	Rattus norvegicus	280-286	
16182256-1	2006	BACKGROUND: Central serotonin2C (5-HT2C) receptors are known to play a role in the mechanism of action of the antipsychotic drugs (APDs) clozapine and haloperidol.	Haloperidol	151-162	5-hydroxytryptamine receptor 2C	Rattus norvegicus	33-39	
16182256-3	2006	METHODS: Using in vivo microdialysis in halothane-anesthetized rats, we assessed the ability of selective 5-HT2C compounds to modulate the release of DA induced by haloperidol and clozapine in the nucleus accumbens and striatum.	Haloperidol	164-175	5-hydroxytryptamine receptor 2C	Rattus norvegicus	106-112	
16182256-5	2006	The effect of .01 mg/kg haloperidol was potentiated by the 5-HT2C inverse agonist SB 206553 (5 mg/kg) but unaltered by the 5-HT2C antagonists SB 243213 and SB 242084 (1 mg/kg).	Haloperidol	24-35	5-hydroxytryptamine receptor 2C	Rattus norvegicus	59-65	
16182256-7	2006	CONCLUSIONS: These results show that clozapine and haloperidol differentially alter the constitutive activity of 5-HT2C receptors and suggest that clozapine behaves as a 5-HT2C inverse agonist in vivo.	Haloperidol	51-62	5-hydroxytryptamine receptor 2C	Rattus norvegicus	113-119	
16182256-7	2006	CONCLUSIONS: These results show that clozapine and haloperidol differentially alter the constitutive activity of 5-HT2C receptors and suggest that clozapine behaves as a 5-HT2C inverse agonist in vivo.	Haloperidol	51-62	5-hydroxytryptamine receptor 2C	Rattus norvegicus	170-176	
1496128-2	1992	The effects of chronic treatment with the atypical antipsychotic, clozapine, and classical antipsychotic, haloperidol, on serotonergic 5-HT-1c and dopamine D2 receptors in rat brain were studied with radioligand binding methods.	Haloperidol	106-117	5-hydroxytryptamine receptor 2C	Rattus norvegicus	135-142	
7898773-5	1994	5-HT2C receptors: clozapine (7.19) > chlorpromazine > risperidone > thioridazine > fluphenazine > spiperone > haloperidol (< 4.00).	Haloperidol	128-139	5-hydroxytryptamine receptor 2C	Rattus norvegicus	0-6	
7851496-1	1994	We studied the effects of acute clozapine and haloperidol treatments on 5-HT2C receptor binding characteristics and 5-HT2C receptor-mediated phosphoinositide hydrolysis in the rat choroid plexus.	Haloperidol	46-57	5-hydroxytryptamine receptor 2C	Rattus norvegicus	72-78	
8386235-5	1993	The 5-HT1C/2 receptor agonist 2,5-dimethoxy-4-bromoamphetamine also completely reversed HAL-induced catalepsy, an effect blocked by ketanserin, but not pindolol.	Haloperidol	88-91	5-hydroxytryptamine receptor 2C	Rattus norvegicus	4-10